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ABSTRACT
Periventricular white matter hyperintensities (pvWMHs) are a neurological feature
detected with magnetic resonance imaging (MRI) and are clinically associated with an
increased risk of stroke and dementia. pvWMHs are characterized by white matter lesions
with myelin and axon rarefaction, and as such likely involve changes in lipid composition,
however these alterations remain unknown. Lipids are critical in determining cell function
and survival, although their detection within tissue, until recently has been challenging.
Perturbations in lipid expression have previously been associated with neurological
disorders.
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imaging
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spectrometry (IMS) is an emerging technique for untargeted, high-throughput
investigation of lipid expression and spatial distribution in situ, however the use of MALDI
IMS has been previously been limited by the need for non-embedded, non-fixed, freshfrozen samples. Work within this thesis demonstrates the novel use of MALDI IMS to
distinguish regional lipid abnormalities that correlate with MRI defined pvWMHs within
ammonium formate washed, formalin-fixed human archival samples. MALDI IMS scans
were conducted in positive or negative ion detection mode on tissue sublimated with 2,5dihydroxybenzoic acid or 1,5- diaminonaphthalene matrices, respectively. Using a broad,
untargeted approach to lipid analysis we consistently detected 116 lipid ion species in 21
tissue blocks from 11 different post-mortem formalin-fixed human brains. Comparing the
monoisotopic mass peaks of these lipid ions elucidated significant differences in lipid
expression between pvWMHs and NAWM for 31 lipid ion species. Expanding our
understanding of alterations in lipid composition will provide greater knowledge of
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molecular mechanisms underpinning ischemic white matter lesions and provides the
potential for novel therapeutic interventions targeting lipid composition abnormalities.
Keywords: CNS, MRI, pvWMHs, neurodegeneration, MALDI TOF IMS, lipids,
lipidomics, multimodal imaging

SUMMARY FOR LAY AUDIENCE
Diseases of the brain, such as Alzheimer’s disease and stroke, represent a major
cause of disability and death, yet many remain uncurable. This is partly due to a limited
understanding of molecular changes that underlie diseases. Of the three categories of
biological macromolecules, which are proteins, lipids, and carbohydrates, lipids are the
most abundant in the brain, accounting for 60% of the dried mass. These lipids contribute
to numerous aspects of cells in the brain including forming the structural walls of cells and
influencing the behaviour of cells. Due to the abundance of lipids in the brain and their
ability to influence cells, they are particularly likely to be altered in diseases of the brain.
Previous studies have demonstrated that changes in lipids are part of many diseases of
the brain, but our understanding still remains limited. This limited understanding is
partially due to the difficulty of studying the enormous variety of lipids that occur in the
brain. Recent improvements in mass spectrometry, a technique for studying lipids, have
opened a door for investigating changes in lipids within diseased brains. In this thesis, we
use this technique to identify lipid abnormalities within diseased post-mortem human
brains. By doing so, we aim to establish a workflow that will allow others to study changes
in lipids that are associated with clinically observable diseases. Research into these lipid
changes may identify therapeutic targets to help manage or cure neurological diseases.
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CHAPTER 1: INTRODUCTION
1.1. The Brain and Neurodegeneration
The central nervous system (CNS) is responsible for an impressive array of tasks
including receiving sensory input, providing motor output, and cognition. The two major
components of the CNS are the grey matter, which primarily contains neuronal cell bodies
and functions to permit the aforementioned tasks, and the white matter, which is made
up of long myelinated neuronal axons and functions to provide communication between
grey matter regions and the body. Grey matter and white matter are mutually dependent
for proper function, and as such, deterioration of either can result in a myriad of clinical
outcomes including chronic disability, decreased quality of life, and death. The societal
and economic impacts of CNS diseases cannot be understated as the chronic morbidity
of CNS diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD),
means that patients will often require decades of expensive care. Worse yet, morbidity
and mortality caused by neurodegenerative diseases will continue to increase with aging
populations around the world1. For example, AD alone costs an estimated 1% of global
GDP and the cost of care is only projected to increase as the global prevalence of AD
patients is estimated to surpass 100 million by 20502,3. The severe impacts of CNS
diseases, for both the patient and society, makes the research of disease etiology,
progression, and treatment imperative to mitigate the impact of CNS diseases.
1.1.2 Neuroimaging
Clinical neuroimaging modalities, such as magnetic resonance imaging (MRI),
positron emission tomography (PET), and computed tomography (CT), are invaluable
resources for detecting and monitoring CNS disease and injury. MRI is the most
1

frequently used clinical imaging modality of the CNS and can detect structural
abnormalities associated with CNS injury, white matter deterioration, and ischemic events
such as stroke4,5. Different MRI pulse sequences, most commonly T1 and T2, can be
used to alter the visualization of different structures. T2 MRI produces high signal intensity
for grey matter and cerebrospinal fluid (CSF), while white matter appears relatively
hypointense. T2 MRI combined with fluid-attenuated inversion recovery (FLAIR) is
commonly used for neuroimaging of white matter pathologies as FLAIR suppresses the
hyperintense signal of CSF thus easing the detection of periventricular white matter
abnormalities6. Whilst MRI is useful for the detection of CNS diseases in clinical patients,
thorough multimodal investigation of MRI-defined post-mortem samples is required for a
greater understanding of the molecular mechanisms underlying clinically observable
pathologies4.
1.2. White Matter Hyperintensities
White matter hyperintensities (WMHs) are an early clinical feature of white matter
degeneration that can be detected with T2-weighted FLAIR MRI7–9. Historically
overlooked as an inevitable feature of ‘normal aging’, recent studies have demonstrated
that WMHs are significantly associated with health risk factors and neurodegeneration10–
12.

These WMHs are clinically associated with a 3-fold increased risk of stroke and 2-fold

increased risk of dementia10. Furthermore, WMHs may contribute to an accelerated rate
of global cognitive decline, independent of other neurodegenerative disorders or injury10.
WMHs are named due to the region appearing bright on MRI relative to the darker signal
typically associated with white matter, a change that is attributed to the occurrence of
localized edema within the tissue13. WMHs are heterogenous in etiology, however,

2

periventricular WMHs (pvWMHs) are believed to occur in part due to cerebral small vessel
disease causing vascular hypoperfusion of the periventricular region resulting in a white
matter lesion14–17. pvWMHs may be observed to be progressive in routine MRI of patients,
a feature associated with a worse neurological prognosis18,19. Histological analysis of
deteriorated white matter was required to enhance our understanding of the clinically
observable feature, however this analysis was delayed due to limitations in detecting
white matter deterioration in post-mortem MRI20,21. This technical limitation has been
ameliorated by improvements in our understanding of MRI signals from formalin-fixed
post-mortem samples to the point that post-mortem MRI is now considered to be suitable
for designating the spatial extent and severity of WMHs20.
Numerous studies using post-mortem histopathological analysis of pvWMHs have
shown rarefaction of both axons and myelin, as well as an increase of microgliosis and
astrocytosis13,21,22. Whilst the loss of myelin alone undoubtedly suggests an alteration in
the lipid content of these regions, very little is known about specific alterations in the
molecular and lipid composition of the tissue underlying pvWMHs. This gap in knowledge
is, in part, due to a lack of techniques available for profiling the lipid composition of
formalin-fixed post-mortem human brain tissue with adequate sensitivity to resolve
differences in the lipid composition of pvWMHs relative to adjacent normal-appearing
white matter (NAWM).
1.3 Lipids
Lipids are biological macromolecules that are critical to the function and survival of
every cell, but are particularly important for proper function of the CNS. Lipids have
incredibly diverse roles, from being constitutive molecules of cell membranes, acting as
3

energy reservoirs, interacting with a plethora of associated biomolecules to influence their
function, and serving as secondary messengers in key cell signalling pathways 23,24. The
functional diversity of lipids is accompanied and accommodated by an even greater
diversity in lipid molecular structures, which influence the chemical, physical, and
biological properties of lipids24,25. This structural and functional heterogeneity contributes
to the difficulty of studying lipid expression and distribution within complex heterogenous
mixtures, such as human brain tissue, a factor which has delayed our understanding of
lipid function. Our understanding of lipid function, while still incomplete, is expanding
through the use of multimodal investigations into the diverse mechanisms by which lipids
influence cells26–28. The technical difficulty of studying lipids within intact biological tissue,
has ameliorated with developments in lipid detection techniques, notable imaging mass
spectrometry (IMS)29,30. Taken together, the critical biological importance of lipids, the
historical difficulty of lipid research, and recent advancements in techniques for the study
of lipids, have resulted in a unique opportunity to expand our understanding of this
understudied trove of biological information.
1.3.1 Lipids in Cell Membranes
The plasma membrane is a dynamic heterogenous bilayer that surrounds
every cell, compartmentalizing them from their environment. These membranes were
often erroneously characterized from a protein-centric view to be relatively passive barrier
that serves to control the flow of molecules and contain the more biologically exciting
membrane-proteins31. It is becoming increasing recognized that these membranes are
heterogeneously composed of diverse lipid species which dramatically influence the
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function of the membrane they create, membrane-associated proteins, and the cell as a
whole24.
Our understanding of the complexities and roles of cell membranes has greatly
expanded in recent decades. Currently it is recognized that, beside their barrier function,
cell membranes are involved in the organization and regulation of numerous cell
signalling pathways23,32. This organization and regulation can occur via membrane
microdomains, previously referred to as lipid rafts, which are small (10-200 nm) regions
of the membrane that are heterogeneously enriched in proteins, sphingolipids such as
gangliosides, and cholesterol33–35. Membrane microdomains are known to undergo
dynamic changes in response to the internal conditions and external environment of the
cell34,35. Interestingly, the lipid component of these membrane microdomains are believed
to be potent modulators of the protein composition and signalling pathways associated
with these microdomains, such as, ganglioside-mediated regulation of the tyrosine
receptor kinase A (TrkA) pro-survival pathway36,37. The molecular mechanisms by which
lipids influence signaling depending on the pathway in question but include lipid-mediated
recruitment of proteins to membrane microdomains and non-covalent lipid-protein binding
to alter protein activity38. The influence of lipids on protein activity can be exemplified by
the ability of specific gangliosides to enhance the activation of the aforementioned TrkA
pro-survival pathway, a phenomenon which will be further discussed later in this
introduction.
1.3.2 Functions – Structural
The plasma membrane is a complex 3D structure that features incredible
biophysical and compositional heterogeneity. It is now known that this heterogeneity,
5

which occurs both laterally and between leaflets of the bilayer, is not a random
phenomenon but rather a complex biophysical system with profound physiological
relevance37. Alterations in physical membrane properties have been demonstrated
influence the activity of transmembrane proteins and peripheral membrane binding
proteins which in-turn affect intracellular signalling pathways23,24. These physical
alterations can be caused by variations in the molecular structures of acyl chains and
head groups of lipids. Alterations in these lipid structures influence the physical
parameters of the membrane including width, fluidity, and curvature. For example,
different lengths and saturations of the acyl chain influence bilayer width, with a longer
chain promoting a wider bilayer width24,39. According to the widely supported ‘hydrophobic
mismatch hypothesis’, this bilayer width subsequently influences the localization and
activity of transmembrane proteins based on the width of their hydrophobic,
transmembrane domain (Fig 1A)39,40.
The tight packing of amphipathic lipids to form a lipid bilayer is an energetic
compromise between the hydrophilic and hydrophobic domains, where neither domain
exists at the lower energy state they would assume when independent from the other 23.
As such, the lipid bilayer exists as a stable yet highly ordered, high-energy structure. This
is driven, in part, by the energetically-favourable association of hydrophilic tails with
adjacent tails and results in the crowding of headgroups at the surfaces of the bilayer.
The crowding of headgroups means that the structural diversity of headgroups present
must be carefully considered when conceptualizing the physical structure of lipid bilayers,
as these hydrophilic domains are constantly influencing the adjacent heads with physical
and ionic interactions23,24. This is demonstrated by the tendency of lipids that contain a
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large head group, such as glycosphingolipids, to induce spontaneous positive curvature
of a lipid membrane (Fig 1B)41. Vice-versa, lipids with a small hydrophilic head, such as
PE, tend to induce negative curvature (Fig 1B)42. When visualized as a bilayer, the
asymmetric distribution of a large headgroup lipid to the outer leaflet and a small
headgroup lipid to the inner leaflet would promote intracellular curvature (Fig 1C). The
biological relevance of this curvature is demonstrated by the necessity of localized lipiddeacetylation/acetylation enzymes to facilitate golgi membrane fission and other lipidregulated membrane deformation events41,43. While our current understanding of lipid
diversity and how it influences the biophysical properties of membranes remains
incomplete, lipids play a critical and often understated role in cell function. Continued
investigation of lipids and how they influence cell function will undoubtedly assist our
understanding and treatment of CNS conditions that include a lipid abnormality
component.

Figure 1. Select examples of the biophysical influence of lipids on lipid membranes.
A) Alterations in the length of the hydrophobic tail, influences the width of the hydrophobic
region of a lipid bilayer. The alterations in-turn influences the localization of
7

transmembrane proteins relative to the width of their transmembrane domain. B) The
physical structure of the head, and its ratio to tail width, influences lipid membrane
curvature. The inverted-cone shape induces spontaneous positive curvature of the
membrane. Conical lipids, those with a head width that is narrower than the tail width,
induce spontaneous negative curvature of the membrane. C) Asymmetrical bilayer
distribution of a conical and inverted-conical lipids can synergistically promote bilayer
curvature. Created with Biorender.com.
1.3.3 Functions – Signalling
The mechanisms by which lipids influence cell signalling pathways are multifaceted,
a diversity which is required to accommodate the diversity of pathways that are
influenced24. This diversity, along with the technical difficulties associated with lipid
investigation, has impeded our understanding of the mechanisms and functions of
specific lipids. Distinguishing the structural and signalling aspects of lipids can be
convoluted as lipids can affect signalling indirectly by influencing the physical parameters
of the plasma membrane, in-turn influencing membrane-associated signalling pathways.
Since some of these structural contributions were previously discussed, this section will
instead provide examples of signalling that aren’t associated with structural functions, and
one interesting example of a structurally-mediated signalling pathway.
One of the most widely known lipid signalling events is the involvement of
phosphatidylinositol 4,5-biphosphate (PIP2) for the transduction and amplification of
certain G-protein couple receptor pathways44,45. In this pathway, the protein
phospholipase C hydrolytically cleaves the head and tail of PIP 2 into the secondary
messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)45. The tail, DAG,
remains embedded in the inner leaflet of the plasma membrane and goes on to activate
members of the protein kinase C family which induce a myriad of downstream effects
including proliferation and differentiation46,47. Meanwhile the head, IP3, now liberated from
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the membrane can diffuse through the cytoplasm and interact with it’s own set of
associated pathways, primarily activating channels that induce intracellular release of
Ca2+45,48. While the downstream signals of DAG and IP3 can vary depending on cell
population and environmental effects, it is clear that these lipid-mediated signalling
pathways are essential for proper cell regulation 48. This is emphasized by the presence
of aberrant PIP2-associated signalling in pathologies such as cancers and AD48. In AD, it
has been demonstrated that beta-amyloid 42 (Aβ42) oligomers associated with AD can
induce intracellular release of Ca2+, which according to the calcium hypothesis of AD is a
cytotoxic insult that may contribute to AD pathology49,50. This release is believed to be
mediated by IP3, as pre-treatment with IP3 receptor antagonists attenuates Ca2+ release50.
Interestingly, mass spectrometry (MS) has been used for the detection of PI species,
including PIP251,52. As such, using MS to investigate lipids within pathological tissues may
elucidate aberrant PIP2 signalling if PIP2 levels were found to be altered within a sample52.
An interesting structurally-mediated signalling pathway is that of the sphingolipid
monosialotetrahexosylganglioside (GM1) and tyrosine receptor kinase A (TrkA). GM1 has
been demonstrated to have neurotrophic effects on mature neurons, however the
mechanisms for this are uncertain and potentially multimodal53–55. One pathway that has
been implicated is the TrkA neuronal pro-survival pathway53. A current theory postulates
that GM1 plays an organizational role, where increased GM1 in the outer leaflet of a
plasma membrane encourages the co-localization of TrkA receptors due to interactions
between the extracellular carbohydrate moiety of GM1 and extracellular domains of
TrkA56. TrkA receptors require dimerization for activation, so increased TrkA receptor
localization enhances the opportunity for TrkA receptor activation without an increase in
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Trk ligands53. As such, the organizational properties of lipids such as GM1 may serve as
potentiators for associated signalling pathways. Numerous studies have demonstrated
robust in situ detection of GM1, and associated gangliosides, from brain tissue samples
using MS57,58. Thus, MS may be able to distinguish ganglioside abnormalities in
pathologies, if they exist, which has the potential to guide future investigation of pathways
associated with lipid abnormalities and how they relate to the pathology.
1.3.4 The involvement of lipids in diseases of the CNS
The abundance of lipids in the brain, as well as, the aforementioned roles of lipids
and lipid metabolites in cell function, means that diseases of the CNS are uniquely prone
to have a lipid perturbation component59. This is supported by the growing recognition of
lipid dyshomeostasis associated with stroke, multiple sclerosis, AD, and Huntington’s
disease59–62. Although

some observational studies

previously attributed

lipids

abnormalities to be end-product alterations associated with the disease, recent
experimental approaches have demonstrated an active role of altered lipids in mediating
disease progression62,63. Lipid dyshomeostasis may play a key role in additional diseases
of the CNS, however, elucidation of lipid abnormalities has been stymied due to the
technical difficulty of specifically and sensitively resolving lipid abnormalities associated
with CNS diseases64. Furthermore, detection and quantification of lipids while retaining
spatial distribution information was historically impossible due to the reliance on
techniques that required tissue homogenization64. Additionally, tissue homogenization
results in the loss of information on lipid alterations that may be specific to distinct cell
populations confounding the results of techniques that require homogenization.
Expanding our knowledge of lipid abnormalities associated with CNS diseases would
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enhance our understanding of potential molecular mechanisms contributing to disease
progression, and provide the opportunity for novel lipid-targeting therapeutics59.
1.4 Mass Spectrometry
MS is a semi-quantitative analytical technique by which a wide variety of molecules such
as proteins, lipids, or metabolites in a sample can be detected65,66. In general, an MS
instrument has three key components, an ion source responsible for the generation of
ions from a sample, a mass analyzer which separates ions by their mass-to-charge ratio
(m/z), and a detector for the subsequent detection of each ion species to generate a mass
spectrum67. A mass spectrum is an output plot displaying relative ion quantity, known as
intensity, on the y-axis with a continuous m/z range on the x-axis67. This versatile
technique permits the simultaneous detection and quantification of a multitude of
ionizable molecules, and as such, research has just begun to scratch the surface of the
questions which MS can be used to investigate.
1.4.1 Imaging mass spectrometry
IMS is currently the only technique that permits simultaneous in situ detection,
quantification, and visualization of multiple small molecules, such as lipid species, within
a single tissue section30,66. IMS functions identically to the mechanism of MS, but the
process is repeated in a stepwise manner to generate individual mass spectra for each
point on the tissue68. This results in the generation of voxels of data, where every pixel in
an intensity map of the tissue has an entire mass spectrum contained within it 68. As such,
IMS permits visualization and relative quantification of every detected ion in the mass
spectra associated with the scanned sample68. The unique ability of IMS to
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simultaneously detect, quantify, and visualize multiple ion species makes IMS an
invaluable tool for lipidomic studies.
1.4.2 MS Ion Sources
MS relies on the use of ions to separate molecules by their m/z and for their
subsequent detection by an ion detector. To produce ions from the sample, MS
instruments have a critical component referred to as the ‘ion source’. Whilst multiple ion
sources exist, they are often categorized as ‘hard’ and ‘soft’ ionization techniques 69. In
brief, these ion sources differ in how they ionize molecules of interest, however, the
differences in ionization influences which molecules are ionized and detected69. Hard
ionization causes relatively large quantities of energy to be transferred from the ion source
to the analyte molecules in the sample, a process which increases the opportunity for
fragmentation to occur69. In contrast, soft ionization imparts minimal energy to the
analytes and risks little to no fragmentation. While hard ionization sources, and the
fragmentation that occurs, can be beneficial for analysis in chemically pure samples,
fragmentation can confound the mass spectra generated from chemically heterogenous
samples, such as tissue samples. For this reason, soft ion sources such as matrixassisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) are often
the preferred technique for tissue analysis69,70. As such, careful consideration and
selection of an ion source is an important facet of planning any MS experiment. The
following subsections will provide a brief discussion of ion sources in the context of
lipidomic investigations.
An additional consideration regarding the detection of lipid ions in MS is that lipid
ions display preferential negative or positive ionization depending on the composition of
12

their headgroup30. As a generalization, negative ion detection scans of human brain tissue
tend to detect [M-H]- ions of phosphatidylethanolamines (PE), phosphatidylserines (PS),
phosphatidylinositols (PI) and acidic sphingolipids30. In-contrast, positive ion detection
spectra of brain tissue are dominated by sphingomyelins (SM) and phosphatidylcholines
(PC), the latter of which are often detected in such abundance that the detection of other
lipid species is suppressed30,71. This abundance of PC and SM species is due to their
quaternary amine group which contains a permanent positive charge30. Whilst negative
lipid ions tend to form as [M-H]-, positive lipid ions commonly form as [M+H]+, [M+Na]+,
[M+K]+30. While these assumptions can help when beginning to interpret a MS dataset, it
must also be considered that other ions exist, such as the dehydration of cholesterol to
form the commonly detected m/z 369.3 [cholesterol-H2O]+ ion72. As such, the variety of
possible ions must be careful considered when analyzing any dataset, a possibility which
can be added by additional MS techniques discussed later.
1.4.3 Ion sources - ESI
ESI has been used as a soft ion source for biomolecules since the 1980s, however,
this technique has several limitations when working with complex heterogenous mixtures
such as biological samples73,74. The process of ESI involves the introduction of a solvent,
evaporation, and development of distinct gas-phase ions75. A key difference between
MALDI and ESI is that the process of ionization in ESI occurs with a liquid-phase to gasphase transition, in contrast to the solid to gas-phase transition of MALDI. This
requirement for a liquid-phase sample means that ESI is incompatible with IMS, as
introduction of a solvent produces in homogenization and loss of spatial information prior
to ionization. Additionally, ESI is susceptible to contamination from salts and other
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endogenously occurring molecules in biological samples76. These contaminants must be
separated from the sample using liquid chromatography prior to ionization. Lastly, ESI is
prone to producing ions with multiple charges73. This phenomenon can be beneficial for
the analysis of large biomolecules, such as proteins, as most MS instruments function
best for the detection of molecules in the <1500 m/z range67. However, the majority of
lipids already occur with a mass of <1500 Daltons and as such do not require multiple
charges to be detected in the <1500 m/z range72. Furthermore, the addition of multiple
charges risks a loss of mass resolution as each additional charge halves the m/z
difference of ions of different masses. The limitations of ESI regarding analysis of
biological samples, lipid detection, and incompatibility with IMS, necessitated the
development of further soft ionization sources.
1.4.4 Ion sources - MALDI
MALDI is a commonly used ion source for lipidomic investigations due to its ‘soft
ionization’ process, meaning that relatively little energy is imparted into the molecule to
generate an ion. Soft ionization is essential for lipid detection experiments as it reduces
the risk of fragmentation occurring, a process that can confound lipid studies as fragments
of larger lipid species are often indistinguishable to intact molecules of smaller related
lipids77. The soft ionization of MALDI is achieved by coating the sample with the desired
matrix, which infiltrates the sample to form crystals around molecules and assists in the
transfer of energy from a laser pulse to the molecules of interest78 (Fig 2). This laser pulse
heats a localized spot to energetically excite the matrix, resulting in the molecules within
undergoing a gas-phase transition and ionization. While the mechanism of ionization
remains uncertain, the dominant theory is gas-phase ionization where the analyte

14

molecules are protonated or deprotonated by surrounding gas-phase matrix ions78,79.
Depending on the matrix chosen MALDI can be suitable for the ionization and detection
of a variety of biomolecules, including proteins, carbohydrates, and lipids 80. Due to the
diversity of molecules that can be detected, the reduced risk of delocalization, and the
minimal fragmentation induced by soft ionization, MALDI was chosen as the ion source
for the experiments discussed in this work.

Figure 2. Schematic of the process of matrix deposition, desorption, and
ionization in MALDI MS. Following matrix application, matrix molecules co-crystalize
with analyte molecules. Upon laser ablation, the matrix assists the gentle transfer of heat
energy from the laser to molecules within the sample. This energy permits the desorption
transition into gas phase, as well as proton transfer to or from the analyte molecules to
ionize them for subsequent TOF and detection. Created with Biorender.com.
1.4.5 Limitations of MALDI
Limitations of MALDI as an ion source include concerns about reproducibility due
to heterogenous matrix application and the semi-quantitative nature of ion detection from
a heterogenous sample30. Fortunately, both limitations can be ameliorated by
methodology.

Homogenous

matrix

application

can

be

achieved

by

matrix

sublimation/deposition, a process which involves heating a known mass of solid-phase
matrix inside a vacuum chamber to induce sublimation, solid to gas-phase transition81.
As the gas-phase matrix diffuses through the chamber it contacts the sample mounted to
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a slide which has been conductively cooled by an ice slush chamber above. This
temperature difference causes deposition, gas to solid-phase transition, homogenously
across the sample. Although matrix application can be improved by the use of matrix
sublimation, the semi-quantitative nature of MALDI MS, is far more difficult to overcome.
Quantification limitations are due to spectrum saturation from the most prevalent ions and
uncertainties in the mechanism of ionization for each matrix82. In a complex biological
sample, it is unlikely that absolute quantification can ever confidently be achieved, as
such, it is best to use MALDI IMS for relative intrasample comparison of detected ions, or
inter-sample comparison of similar tissues that have been identically prepared.
1.4.6 Mass analyzers
As previously mentioned, mass analyzers are a critical component of any MS
instrument, responsible for the separation of ions by their m/z. While various mass
analyzers exist, they typically function by using charged fields to control the movement of
gas-phase ions produced from the sample. As with other facets of the MS instrument,
selection of a mass analyzer should be unique to each experiment. This is due to
differences in the three key characteristics of mass analyzers; mass accuracy, the
accuracy of experimental m/z values to actual m/z values, mass resolution, the m/z limit
at which the analyzer can distinguish two mass peaks, and mass range, the range, and
limits of m/z values that an analyzer can be used for83. Commonly used mass analyzers
include time-of-flight (TOF), quadrupole, and quadrupole ion trap. Detailed discussion of
the types of mass analyzers and their mechanisms exceeds the scope of this introduction,
but several in-depth reviews on the topic exist83,84.
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1.4.7 Time-of-flight mass analyzers
TOF is a commonly used mass analyzer due to its rapid mass spectrum acquisition
speed, and high mass accuracy, mass resolution and mass range 83. In a MALDI-TOFIMS instrument, TOF occurs following MALDI when analyte molecules have already
undergone gas phase transition and ionization (Fig 3A). The analyte ions are passed
through a series of magnetically charged gates causing them to accelerate through a
flight tube. This flight tube serves to separate analyte ions based on both their mass and
charge since heavier molecules will fly slower than lighter molecules of identical charge.
At the end of the flight tube a detector measures both the time is takes for ions to arrive,
which permits the assignment of m/z values to these ions, and the quantity of ions arriving
at a given m/z, allowing the user to semi-quantitatively interpret the number of ions
generated from a sample. Due to the benefits of TOF, such as rapid acquisition of broad
mass spectra, TOF mass analyzers are particularly suited for lipidomic investigations.
1.4.8 Ion identification and MALDI TOF/TOF tandem mass spectrometry
Ion identification is a necessary part of any MS experiment, and can be a
particularly difficult task in untargeted, shotgun-style analysis of molecularly-complex
samples such as human tissue30. Ion identities can be assigned by accurate mass, by
which the experimental m/z value is compared to theoretical m/z values, however, this
approach is limited by both the mass accuracy of the instrument and the inability to
distinguish ions of identical m/z such as structural isomers which commonly occurs with
lipids30,72. As such, tandem mass spectrometry (MS/MS) is the gold-standard for
identification of ions detected in MS experiments30,72. MS/MS differs from standard MS
by coupling two mass analyzers in sequence (Fig 3B). This permits the selection of ions
detected at a specific m/z value in the first mass analyzer, annotated as MS1, causing all
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other ions to be gated out of the second mass analyzer, MS 2. Before the selected ions,
known as precursor ions, reach MS2, they are subjected to fragmentation into product
ions, which enables the production of a ‘fingerprint-like’ mass spectrum at MS2 based on
the m/z of each product ion fragment. The product ion fragments that a molecule can
produce are often predictable based on its molecular structure and its innate tendency to
fragment at certain bonds85. A prime example of this is the tendency for the lipid head
group, or a portion of it, to fragment away. This headgroup fragment alone can
dramatically assist lipid identification by indicating the lipid class from which parent ion
originated (Table 1). MS/MS is an invaluable identification technique for heterogenous
samples that contain many distinct molecules occurring at similar m/z ranges, such as
lipids in human brain tissue.
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Figure 3. Schematic of mass analysis by TOF and TOF/TOF MSMS following MALDI.
A) Following MALDI, gas phase ions are accelerated into a flight tube by a potential
difference between the sample plate and a series of charged gates. Molecules of identical
charge receive the same amount of kinetic energy, causing heavier molecules to fly
slower than lighter molecules of the same charge. This separation of molecules based on
their m/z as they move through the flight tube causes them to reach the detector at
different times which assigns an m/z value to each molecule based on its relative arrival
time. B) TOF/TOF MSMS is achieved by connecting two TOF mass analyzers in
sequence. This permits the selection of molecules at a given m/z by gating other
molecules out of the second analyzer. Selected molecules then undergo fragmentation,
and the product ions of the precursor species are subjected to TOF and subsequent
fragment analysis for precursor identification. Created with Biorender.com.
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Lipid Category

Product Ion
m/z

Product Ion Identity

General phospholipids

79
153
171

[phosphate-H][glycerol phosphate-H2O-H][glycerol phosphate-H]-

PE

196.0
M-43

[Phosphoethanolamine-H2O-H][Precursor-ethanolamine]-

PI

241

[Inositolphosphate-H2O]-

PS

M-87

[Precursor-serine]-

Acidic glycosphingolipids
(Gangliosides)

290

[N-acetylneuraminic acid-H]-

Table 1. Summary of characteristic lipid fragments observed in negative mode
MSMS. Summary of characteristic lipid fragments previously observed in MSMS product
ion spectra generated from lipids. Relevant citations for all ion species are in the main
text.
1.4.9. MALDI IMS of lipids
Historically, technical limitations prevented detection and quantification of lipids
while maintaining both spatial distribution and lipid species specificity. This is due to
techniques relying on either immunohistochemistry, which maintains spatial distribution
but loses specificity for the hydrophobic domain, or analysis of extracted homogenized
tissue which causes loss of spatial distribution information 72. Throughout the 1990s and
2000s this barrier was breached by the application of MALDI IMS for in situ detection of
biomolecules86,87. Since then, MALDI IMS has been applied for the detection of diverse
lipid species within numerous human tissues including brain, liver, and various tumours.
In these tissues, MALDI IMS has detected sub-classes of phospholipids and sphingolipids
(SP), such as PCs, PIs, and gangliosides, which are known to influence cell function and
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survival82. As such, detection of these lipids within a sample can improve our
understanding of molecular pathways occurring within the sample.
An interesting application of MALDI IMS is for the elucidation of regional lipid
abnormalities within a tissue sample, as shown by the detection of lipid disturbances in
pathological tissues such as stroke injuries60. This application of MALDI IMS allows for in
situ detection, visualization, and quantification of multiple lipid species within a sample,
allowing for a lipidomic-level approach to identifying differences between pathological
regions and adjacent healthy regions within a single sample. Such an approach can be
used for either experimental investigation or diagnostically. Work within this thesis will
focus on the use of MALDI IMS for experimental investigation of tissues and their lipid
profiles. The investigative application of MALDI IMS for distinguishing regional lipid
abnormalities has previously identified abnormalities in diverse lipid classes such as PCs,
PIs, PEs, and SP. These studies enhance our knowledge of the molecular mechanisms
that underlie pathologies and provide novel treatment avenues by identifying
dysregulated lipids that may be targeted to ameliorate disease progression.
1.4.10 Tissue preservation and MALDI IMS
Post-mortem tissue preservation is a critical step to maintain morphological and
molecular fidelity. These post-mortem alterations, which begin to occur within minutes,
are most commonly prevented by chemical-fixation with formalin, formaldehyde, or
paraformaldehyde which prevent post-mortem deterioration, in part, by cross-linking
proteins to prevent their enzymatic activity88. Chemical-fixation techniques are commonly
used due to the ease of the preservation protocol and samples not requiring expensive
cold storage88. As such, robust tissue banks containing chemically-fixed samples with
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clinical associations have been developed for post-mortem analysis. However, the goldstandard tissue for MALDI MS has long been fresh-frozen tissue, tissue which is snapfrozen soon after extraction58,89. Indeed, MALDI MS was previously believed to be
incompatible with formalin-fixed tissue, largely due to fixation causing the cross-linking of
proteins and the concerns that fixatives inhibit the detection of lipid molecules58,89. While
fixatives may inhibit the detection certain lipid classes, such as PEs, recent studies have
demonstrated that detection of both proteins and lipids from formalin-fixed archive tissue
is possible with MALDI MS58,89,90. As such, numerous archived formalin-fixed clinicallyrelevant tissue samples can now be investigated using MS to elucidate molecular
abnormalities associated with pathologies.
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1.5 Rationale
Lipids play a critical and dynamic role in regulating cell function and survival. Lipid
abnormalities observed in various pathologies, such as AD, stroke, cancers, and multiple
sclerosis, are now known to play a role in disease progression. Whilst lipid abnormalities
have been observed in some CNS diseases, the technical limitation of lipid detection in
clinically-relevant formalin-fixed human archival tissue has prevented a greater
understanding of specific lipid species alterations. MALDI IMS is a molecular imaging
technique that permits untagged, in situ quantification and visualization of a variety of
molecules, including multiple lipid classes. To our knowledge, MALDI IMS has never
previously been applied to distinguish regional lipid abnormalities within MRI-defined
formalin-fixed post-mortem human brain tissue. Combining current clinically relevant
imaging techniques, such as MRI, and lipidome analysis with MALDI IMS will permit the
identification of regional lipid abnormalities associated with pathologies. By elucidating
regional lipid abnormalities, we will better understand clinically observable neurological
features, disease mechanisms, and progression, as well as provide novel lipid-based
targets for therapeutic intervention.
1.6 Aim and Hypothesis
Aim: Investigate the application of MALDI IMS for unbiased, shotgun-style
investigation of neuroanatomical-specific lipid abnormalities within MRI-defined, postmortem, formalin-fixed human CNS tissue.
Hypothesis: Lipid abnormalities exist within pathological white matter regions
identified using post-mortem T2-weighted FLAIR MRI, and MALDI IMS can resolve these
abnormalities relative to adjacent normal-appearing white matter.
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CHAPTER 2: METHODS
2.1 Specimen Selection for MRI Imaging
Specimen for MRI imaging were chosen based on neuropathological findings
documented by a certified Neuropathologist at autopsy. Intact brains were obtained from
a bank of samples that had been stored in 10% neutral buffered formalin for up to 15
years following previous neuropathological examination. One coronal slice from the
frontal lobe of each specimen was selected for imaging. The final selection for MRI
imaging included 20 specimens. Demographic data for the 20 specimens can be found in
Supplementary Table 1.
2.2 MRI Brain Imaging
All scans were performed at Robarts Research Institute’s Centre for Functional
and Metabolic Mapping on a MAGNETOM 7T MRI Scanner (Siemens). Coronal slices of
fixed tissue from the frontal lobes of the brain were removed from formalin and immersed
in Galden HT-270 perfluorinated fluid (Kurt J Lesker Company, Vaughan, ON, Canada).
5 coronal sections were scanned simultaneously using a custom-made stacking device
until coronal sections from all 20 specimens were scanned. The stacking device was
secured into the head coil apparatus for scanning. Structural MRI images were acquired
in the coronal orientation with the following sequences: 3D T1-weighted MPRAGE (1 mm
slice thickness, TR/TE=3000/1.72 ms, flip angle =90, FOV= 160 x 126 mm , in-plane
resolution of 0.7 x 0.7 mm), 3D T2-weighted SPACE sequence (1mm slice thickness,
TR/TE=2500/349 ms, flip angle= 90 FOV = 160 x 120 mm, in plane resolution of 0.5 x 0.5
mm) and 3D FLAIR sequence (1mm slice thickness, TR/TE/T1=8000/205/1600 ms, flip
angle= 90, FOV= 160 x 120 mm, in-plane resolution of 0.63 x 0.63 mm).
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2.3 Specimen Selection for MALDI TOF IMS Scanning
PvWMHs from the cohort of MRI-scanned specimens were qualitatively evaluated
using a modified version of the Fazekas’ rating scale 91. Eleven brain specimens were
selected for MALDI TOF IMS imaging that met the MRI-criteria for “moderate pvWMH”,
which involved a lesion that extended greater than 1/3 of the distance between the edge
of the ventricle and the cortex. Nine of these brain specimens had bi-lateral moderate
periventricular WMHs, the remaining two brain specimens were scored as moderate
periventricular WMH for only one hemisphere. As such, a total of 20 distinct moderate
pvWMHs from 11 brain specimens were selected for MALDI TOF IMS scanning. These
specimens represent a heterogenous group with neuropathological diagnoses of
Alzheimer’s disease and/or cerebrovascular disease. Remaining specimens from the
MRI-scanned cohort were excluded due to an evaluation of less than or more than
“moderate pvWMH” on the modified Fazekas’ ratings scale.
2.4 Tissue blocking
Tissues containing periventricular white matter were sampled for tissue selection
based on MRI findings. Tissue blocks were obtained from brain tissue that included the
moderate pvWMH, subcortical white matter and cortical tissue. Block were stored in 10%
neutral buffered formalin prior to processing. The anatomy of the cortex and subcortical
structures was used to correctly match the tissue to the corresponding MRI image.
2.5 Tissue Sectioning and Mounting
Formalin-fixed non-embedded tissue blocks were sectioned at 10 µm thickness
using a Cryostar NX50 cryostat (Thermo-Fisher Scientific, Toronto, ON, Canada) at 25

25oC. Tissue sections were then thaw-mounted to electrically conductive indium-tin-oxide
coated slides (Hudson Surface Technology Inc., Old Tappan, NY, USA).
2.6 Ammonium Formate Wash
Ammonium formate (AF) washes were performed to enhance lipid signal from
formalin-fixed tissue as previously described58.
2.7 Matrix Sublimation
Mounted tissue sections were placed into a sublimation apparatus (Chemglass)
for sublimation with either DAN matrix (Sigma-Aldrich, Oakville, ON, Canada) for negative
ion mode scans or DHB matrix (Alfa Aesar, Haverhill, MA, USA) for positive ion mode
scans. Assembly of apparatus and sublimation of DAN57 and DHB92 was performed as
previously described.
2.8 MALDI-TOF-IMS
MALDI TOF IMS was performed using a Sciex 5800 TOF/TOF system, MALDI
TOF/TOF (Sciex, Framingham, MA, USA) equipped with a 349 nm Nd:YLF OptiBeam
On-Axis laser using a laser pulse rate of 400 Hz as previously described 58. Reflectron
negative scans were conducted from m/z 450-1000 and m/z 1000-2000. Reflectron
positive scans were conducted from m/z 450-1000. TOF TOF Series Explorer (Sciex) and
Data Explorer (Sciex) software were used for data acquisition and processing,
respectively.
2.9 Image and Data Analysis
MALDI IMS data was visualized using TissueView software (Sciex). Manual
selection of Region of Interests (ROIs) in white matter that appeared normal on MRI
(NAWM), and periventricular white matter that appeared hyperintense with MRI (pvWMH)
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was performed through co-visualization of MALDI TOF IMS images and reference MRI
scans. Average mass spectra per ROI were then simultaneously generated for each ROI.
Mass peaks were acquired from each mass spectra based on our established criteria of
a minimum signal-to-noise ratio (SNR) >3. Mass peaks that did not meet the SNR criteria
were omitted. Mass peaks were assessed for consistent detection (>80%) in scans from
all 21 tissue blocks. Mass peaks which were consistently detected in >80% of scans were
carried forward for statistical analysis. Intensity values corresponding to the monoisotopic
peak of consistently detected mass peaks were isolated for intrasubject comparison.
2.10 Identification of Lipid Ions by Searching Experimental m/z in LMISSD and
SwissLipids
Identification of mass peaks was primarily conducted by using experimental m/z
values to interrogate the LIPID Metabolites and Pathway Strategies (MAPS) In Silico
Structural Database (LMISSD)93. A second independent database, SwissLipids, was
interrogated using the same approach. Database searches were conducted with the
following parameters:
Experimental m/z searches of mass peaks detected in negative ion mode:
Mass Tolerance (m/z): ± 0.1
Ion Adducts: [M-H]Experimental m/z searches of mass peaks detected in positive ion mode:
Mass Tolerance (m/z): ± 0.1
Ion Adducts: [M+H]+, [M+Na]+, [M+K]+
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LMISSD resource available at:
https://www.lipidmaps.org/resources/databases/lmissd/search.php.
SwissLipids resource available at:
https://www.swisslipids.org/#/advanced
2.11 Identification of Previously Unidentified Mass Peaks by MALDI TOF Tandem
Mass Spectrometry
To assist the identification of select mass peaks in negative low-range, tissue was
prepared for MALDI TOF IMS imaging and subjected to tandem mass spectrometry
(MSMS) in the Sciex 5800 TOF/TOF system, MALDI TOF/TOF (Sciex, Framingham, MA,
USA). Reflectron negative mode was used to generate negative MSMS from parent
peaks in the m/z 450-1000 range and m/z 1000-2000 range. Reflectron positive mode
was used to generate positive MSMS from parent peaks in the m/z 450-1000 range.
Reflectron modes were externally calibrated at 50 ppm mass tolerance and internally at
10 ppm mass tolerance. TOF/TOF Series Explorer (Sciex) and Data Explorer (Sciex)
software were used for data acquisition and processing respectively. MSMS product ion
spectra were visualized using LipidBlast85. MSMS search criteria were set using the
previously described recommendations85. Manual interrogation of MSMS product ion
spectra was performed to identify the presence of characteristic lipid class peaks.
2.12 Statistical Analysis
Intrasubject lipid comparison was conducted by comparing monoisotopic intensity
values of NAWM to pvWMH for every mass peak that was detected in >80% of the 21
tissue blocks scanned. Paired two-tailed Student’s t-tests were used to test for
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significance between NAWM and pvWMH for each mass peak. A p-value of <0.05 was
considered significant. N indicates biological N-value.

CHAPTER 3: RESULTS
3.1 Lipid Detection Metrics
Analysis of MALDI IMS spectra from all 21 tissue blocks yielded a total of 87 unique
ions in negative ion high-range scans, 125 unique ions in negative ion low-range scans,
and 96 unique ions in positive ion low-range scans (Table 2). These mass peaks were
then assessed between for consistent detection in all specimens (observed in >80% of
the 21 tissue blocks). A total of 30 ions from negative ion high-range scans, 41 ions from
negative ion low-range scans, and 45 ions from positive ion low-range scans were carried
forward for statistical evaluation.
Scan Mode

Total Ion Species

Negative ion m/z 1000-2000

87

Ion Species with >80%
Detection
30

Negative ion m/z 450-1000

125

41

Positive ion m/z 450-1000

96

45

Table 2. MALDI IMS of formalin-fixed post-mortem human white matter consistently
detected 116 ion species. Peaks detected in mass spectra generated using a Sciex
5800 TOF/TOF system, from post-mortem human brain tissue using Reflectron negative
and positive ion modes with DAN and DHB matrices, respectively.
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Figure 4. Annotated MALDI-TOF mass spectra of post-mortem human white matter.
Representative white matter mass spectra annotated with tentative lipid ion identities for
mass peaks that were significantly altered between pvWMH and NAWM. A) Negative ion
mass spectrum m/z 1000-2000 obtained from tissue sublimated with 1,5-DAN matrix in
negative ion detection mode. B) Negative ion mass spectrum m/z 450-1000 obtained from
tissue sublimated with 1,5-DAN matrix in negative ion detection mode. C) Positive ion
mass spectrum m/z 450-1000 obtained from tissue sublimated with 2,5-DHB matrix in
positive ion detection mode.
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3.2 Negative ion MALDI IMS scans detect regional lipid abnormalities within
pvWMHs – m/z 1000-2000 Range
Intrasubject comparison of negative ion spectra at m/z 1000-2000 elucidated
significant differences in 10 of the 30 mass peaks assessed (Fig. 5, Table 1). An increase
of monoisotopic peak intensities in the pvWMH relative to NAWM were observed for the
ion species occurring at m/z = 1572.9 and 1544.9 (Fig. 5). Decreases in monoisotopic
peak intensities were observed for the ions at m/z = 1303.1. 1288.1, 1170.0, 1153.0,
1135.8, 1133.8, 1110.8, and 1108.8 (Fig. 5).
Identities were assigned to lipid ions by searching two independent lipid
databases, LMISSD and SwissLipids, with experimentally generated m/z values using the
parameters described in our methods (Fig. 5, Table 3). This method for identity
assignment often yielded multiple tentative identities that were indistinguishable at MS 1,
as such, on-tissue MALDI MSMS was performed to assist in lipid class assignment. We
attempted to generate MALDI MSMS product ion spectra from all significantly different
mass peaks, however, not all mass peaks produced conclusive MALDI MSMS product
ion spectra. MALDI MSMS product ion spectra were manually interrogated for the
presence of characteristic fragments to assist confident assignment of lipid class, a similar
approach taken by previous untargeted MALDI MS investigations 87. Detailed structural
characterizations of select product ion spectra, such as from the precursor occur at m/z
= 1544.9 (Fig. 6), were performed, however complete characterization of all species is
beyond the scope of the current investigation.
All product ion spectra generated from precursors detected in negative high-range
scans, excluding the precursor ions occurring at m/z = 1572.9 and 1544.9, produced
fragment ions at either m/z = 153, 171, or both (Table 3). These product ion fragments
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correspond to [glycerol phosphate-H2O-H]- and [glycerol phosphate-H]-, respectively, as
such, precursor ions that fragment to produce these product ions can be unambiguously
identified as glycerophospholipids (Table 1, 3).
Following unambiguous confirmation that all significantly altered species,
excluding the precursor ions occurring at m/z = 1572.9 and 1544.9, were in fact
glycerophospholipids, lipid class assignment was attempted by manually assessing
product ion spectra for the presence of characteristic fragments. Table 1 provides a
summary of previously published characteristic lipid fragments that may be observed in
negative mode product ion spectra generated from major lipid classes detectable using
MALDI IMS in human brain tissue30,94–96
The product ion spectra of the precursor ions occurring at m/z = 1572.9 and 1544.9
both contained prominent fragment peaks at m/z = 290.0, a characteristic fragment of
gangliosides which corresponds to [N-acetylneuraminic acid-H]- (Table 1, 3)58. Detailed
structural characterization of the precursor ion occurring at m/z = 1544.9 was performed
using the MALDI MSMS product ion spectra (Fig. 6). The presence of the [Nacetylneuraminic

acid-H]-

fragment

supports

the

confident

assignment

of

monosiayloganglioside (GM) species [GM1 38:1-H]- (d20:0) and [GM1 36:1-H]- (d18:0) to
m/z = 1572.9 and 1544.9, respectively, as has been identified in previous publications 97.
Our experimental m/z value for the species occurring at m/z 1303.1 failed to
provide reliable identification in either lipid database used. Analysis of the MALDI MSMS
product ion spectra from this peak was inconclusive, possibly due to the low SNR of the
precursor. However, product ion peaks were observed at m/z 97.0 and 171.0, known
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phospholipid headgroup fragments, confirming that the ion occurring at m/z 1303.1 is a
phospholipid of unknown identity.

Figure 5. High range negative ion detection MALDI IMS scans distinguished
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in postmortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red
asterisk indicates region identified as a pvWMH. Black box indicates approximate area
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline
indicates a region of NAWM. B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on postmortem human brain tissue sublimated with 1,5 DAN matrix. Intensity maps generated
from (C) [GM1 36:1-H]- and (D) [PI O-68:6-H] -. Scale bars = 5 mm. E) Pseudocoloured
intensity maps showing the overlay of [GM1 36:1-H]- and [PI O-68:6-H] -. F)
pvWMH:NAWM fold-change of monoisotopic peak intensity for statistically significant
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lipids. Data presented as mean(SD). * indicates p<0.05,**p<0.01, ***p<0.001 via twotailed Student’s T-Test (n=18-20).
Experimental
Product Ion
Tentative
Theoretical
Mass Error
m/z
m/z (MSMS)
Identification
m/z
(ppm)
1572.8999

87.0, 154.0, 289.9, 790.3,
916.9, 1283.7

[GM1 38:1-H](d20:0)

1572.9007

-0.5073

1544.8690

87.0, 154.0, 290.0, 561.8,
726.6, 790.3, 888.5, 1254.0

[GM1 36:1-H](d18:0)

1544.8694

-0.2466

1303.0667

97.0, 171.0, 435.4, 663.9,
793.9, 1171.1, 1234.8

Unidentified

N/A

N/A

1288.0513

87.0, 153.0, 171.0, 435.3,
496.2, 669.5, 795.9, 951.0,
1206.0

[PI (O-68:6)H]-

1287.9807

54.8146

1169.9988

97.0, 153.0, 171.0, 281.2,
433.3, 644.3, 723.9, 989.6

[PG 64:0-H]-

1170.0033

-3.8795

1152.9863

78.9, 153.0, 171.0, 281.2,
456.8, 569.5, 699.0, 798.4,
1096.0

[PS 62:1-H]-

1152.9516

30.1062

1135.8073

153.0, 171.0, 255.2, 281.3,
435.3, 620.1, 882.9, 935.7

[PI 56:5-H]-

1135.8159

-7.6262

1133.7919

153.0, 171.0, 226.0, 409.2,
686.3, 694.9, 728.6, 936.8

[PI 56:6-H]-

1133.8003

-7.4025

1110.8079

153.0, 171.0, 401.2, 459.1,
684.6, 743.9, 783.8, 790.3,
797.6, 889.2 931.7

[PS(60:8)-H]-

1110.8108

-2.6107

1108.8065

153.0, 171.0, 417.2, 649.6,
686.4, 740.1, 790.6, 905.0

[PS(60:9)-H]-

1108.7951

10.2814

Table 3. Identification of significantly altered lipid ions detected in negative ion
high-range scans by database interrogation and negative mode on-tissue MALDI
MSMS in formalin-fixed post-mortem human white matter. Peaks detected in mass
spectra generated using a Sciex 5800 TOF/TOF system, from DAN-coated post-mortem
human brain tissue in negative ion mode at m/z 1000 – 2000. Theoretical m/z values and
identification based on experimental m/z searches in LMISSD and SwissLipids,
complemented with manual interrogation of on-tissue MALDI MSMS as described in
Methods.
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GM1 38:1
m/z 726

m/z 290, 1253

m/z 564

Figure 6. On-tissue negative mode MALDI MSMS characterization of the
precursor peak occurring at m/z 1544.9. On-tissue MALDI MSMS of the peak at m/z
1544.9 produced fragments characteristic of [GM1 38:1-H]- (d20:0). MSMS product ion
spectra visualized using LipidBLAST software85. MALDI MSMS was performed at
described in Methods. GM1 38:1 molecular structure visualized from LMISSD93.

3.3 Negative ion MALDI IMS scans detect regional lipid abnormalities within
pvWMHs – m/z 450-1000 Range
Analysis of negative ion scans conducted at m/z 450-1000 revealed differences in
expression for 11 of 41 consistently detected ion species (Fig. 7, Table 4). Increased peak
intensity was observed for the ions occurring at m/z = 932.6, 920.6, 916.6, 878.7, 876.7,
715.6, 644.4, 599.2, 597.2, and 563.3 (Fig. 7). The intensity of the mass peak at m/z =
647.0 was found to be significantly decreased in WMHs relative to NAWM (Fig. 7).
Assignment of ion species to significant mass peaks in negative ion low range
scans was performed by experimental m/z searches in LMISSD and SwissLipids (Table
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4). Similarly to the identification of ion species in the higher range negative ion detection
mode, on-tissue MALDI MSMS spectra were generated to assist the confident
assignment of lipid ion identities. We attempted to generate negative ion MSMS spectra
from all significantly altered precursor species, however, the ion species occurring at m/z
= 878.7, 876.7, 644.4 failed to generate viable MSMS spectra. Similar to product ion
spectra generated from high range negative ion precursors, product ion spectra in this
range showed fragments at m/z = 79, 153, 171 (Table 4). As previously reported, these
fragments are characteristic fragments of glycerophospholipids, confirming that all altered
lipid ion species in low range negative ion scans are glycerophospholipids (Table 1, 4).
Using this strategy, we assigned tentative lipid ion identities to all mass peaks,
except for the mass peak occurring at m/z = 647.0 in negative ion low range scans (Table
4).
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Figure 7. Low range negative ion detection MALDI IMS scans distinguished
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in postmortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red
asterisk indicates region identified as a pvWMH. Black box indicates approximate area
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline
indicates a region of NAWM. B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on postmortem human brain tissue sublimated with 1,5 DAN matrix. Intensity maps generated
from (C) [Hex1Cer 34:0-H]- and (D) the mass peak occurring at m/z 647.0. Scale bars =
5 mm. E) Pseudocoloured intensity maps showing the overlay of [Hex1Cer 34:0-H]- and
the mass peak occurring at 647.0 m/z. F) pvWMH:NAWM fold-change of monoisotopic
peak intensity for statistically significant lipids. Data presented as mean(SD). * indicates
p<0.05,**p<0.01, ***p<0.001 via two-tailed Student’s T-Test (n=18-20).
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Experimental

Product Ion
m/z (MSMS)

m/z

Tentative

Theoretical Mass Error

Identification

m/z

(ppm)

932.6431

59.0, 97.0, 119.0,
241.0, 568.4.0,
749.1, 888.9

[PS 47:6-H]-

932.6386

4.8357

920.6273

97.0, 119.0, 153.0,
241.0, 283.0, 327.0,
419.2, 522.3, 542.3,
581.2, 727.0, 880.0

[PS 46:5-H]-

920.6386

-12.2719

916.6389

59.0, 97.0, 119.0,
124.4, 241.1, 540.4,
871.2

[ST 44:2-H]-

916.6548

17.3023

878.6607

N/A

[PE 46:4-H]-

878.6644

-4.2462

876.6714

N/A

[PE O-47:5-H]-

876.6852

-15.7183

716.5751

79.0, 153.0, 171.0,
226.0, 281.2, 419.3,
505.4
N/A

[Hex1Cer 34:0-H]-

716.5682

9.6516

Unidentified

N/A

N/A

644.4351

79.0, 153.0, 171.0,
226.1.0, 281.2,
479.3, 505.4

[PE 29:2-H]-

644.4297

8.4307

599.2397

79.0, 140.0, 153.0,
171.0, 255.2, 283.3,
419.4, 535.0

[PI 16:0(Ke)-H]-

599.2474

-12.8194

597.2254

79, 97, 153, 255.2,
283.3, 419.3, 535.5

[PI 16:1(Ke)-H]-

597.2318

-10.6742

563.2596

79.0, 153.0, 171.0,

Indistinguishable

563.2627

-5.5036

226.2, 308.5, 394.4,

structural isomers

489.5

(Oxidized

646.9677

glycerophospholipids)
Table 4. Identification of significantly altered lipid ions detected in negative ion lowrange scans by database interrogation and negative mode on-tissue MALDI MSMS
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in formalin-fixed post-mortem human white matter. Peaks detected in mass spectra
generated using a Sciex 5800 TOF/TOF system, from DAN-coated post-mortem human
brain tissue in negative ion mode at m/z 450 – 1000 m/z. Theoretical m/z values and
tentative IDs based on experimental m/z searches in LMISSD, SwissLipids,
complemented with manual interrogation of on-tissue MALDI MSMS as described in
Methods.
3.4 Regional phosphatidylcholine and sphingomyelin abnormalities detected
using positive ion MALDI IMS scans within pvWMHs
Spectra generated at m/z 450-1000 in positive ion mode showed significant
increases in the four ion species detected at m/z = 764.8, 734.7, 725.6, and 703.6 (Fig.
8), with a simultaneous decrease in the six ion species detected at m/z = 848.7, 774.7,
772.7, 746.7, 550.4, and 504.4 (Fig. 8).
Identification of previously unidentified positive ion mass peaks was performed by
experimental m/z searches of the LMISSD and SwissLipids databases (Table 5). Ontissue MALDI MSMS was also conducted in positive ion detection mode (Table 5). Using
this approach, we identified all significantly different mass peaks detected in positive
mode scans, except for the mass peaks detected at m/z = 764.8 and 734.7 (Fig. 8, Table
5).
Manual interrogation of positive ion product spectra generated using on-tissue
MALDI MSMS revealed the presence of a characteristic PC and SM headgroup
fragment98, m/z 184 = [phosphocholine+H]+, in all product spectra (Table 5). The
presence of this headgroup fragment in all product spectra generated from species
detected in positive mode confirms that positive mode MALDI IMS scans of white matter
tissue abundantly detects PC and SM species99. Due to the presence of a product ion
fragment at m/z 184, database searches in LMISSD and SwissLipids for species detected
in positive mode scans were limited to lipid species which contain a phosphocholine in
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their headgroup, an approach which dramatically reduced the number of potential
identities.

Figure 8. Low range positive ion detection MALDI IMS scans distinguished
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in postmortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red
asterisk indicates region identified as a pvWMH. Black box indicates approximate area
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline
indicates a region of NAWM. B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on postmortem human brain tissue sublimated with 2,5 DHB matrix. Intensity maps generated
from the mass peak occurring at (C) [SM 34:1+H]+. and (D) [PC O-34:3+Na]+. Scale bars
= 5 mm. E) Pseudocoloured intensity maps showing the overlay of [SM 34:1+H]+ and PC
O-34:3+Na]+. E) pvWMH:NAWM fold-change of monoisotopic peak intensity for
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statistically significant lipids. Data presented as mean(SD) * indicates p<0.05,**p<0.01
via two-tailed Student’s T-Test (n=16-20).
Experimental
m/z

Product Ion
m/z (MSMS)

Tentative
Identification

Theoretical
m/z

Mass Error
(ppm)

848.7224

39.0, 86.1, 104.1, 163.0,
184.1, 224.0, 454.3, 480.2,
542.6, 659.4, 705.8, 763.9,
792.8, 793.7

[PC O-40:3+Na]+

848.6504

84.8524

774.6687

39.0, 86.1,184.1, 198.1,
390.2, 512.3, 713.9

[PC O-36:1+H]+

774.6372

40.6642

772.6563

39, 86.1,184.1, 198.1, 392.3,
628.6, 711.5

[PC O-36:2+H]+

772.6215

45.0416

764.7509

184.0, 369.3, 410.9, 468.9,
561.2, 632.6, 697.1, 710.5

Unidentified

N/A

N/A

746.6560

86, 184.1, 389.4, 482.3,
683.4

[PC O-34:1+H]+

746.6058

67.2376

734.7445

184.0, 341.4, 419.3, 537.4,
579.4, 608.9, 639.3, 648.5

Unidentified

N/A

N/A

725.6122

37.8, 169.1, 184.0, 307.2,
400.2, 430.8, 567.1, 670.4

[SM 36:4+H]+

725.5592

73.047106

703.6105

171.1, 184.1, 425.2, 520.2,
525.5, 599.3, 634.4, 652.4

[SM 34:1+H]+

703.5749

50.5987

550.4082

184.1, 264.3, 401.4, 487.5,
503.7

550.3867

39.0634

504.3605

60.0, 104.1, 184.0, 342.8,
382.2, 436.3, 446.1

Indistinguishable
[PC or LPC+H
H]+
[LPC O16:0+Na]+

504.3424

35.8883

Table 5. Identification of significantly altered lipid ions detected in positive ion lowrange scans by database interrogation and positive mode on-tissue MALDI MSMS
in formalin-fixed post-mortem human white matter. Peaks detected in mass spectra
generated using a Sciex 5800 TOF/TOF system, from DHB-coated post-mortem human
brain tissue in positive ion mode at m/z 450 – 1000 m/z. Theoretical m/z values and
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tentative IDs based on experimental m/z searches in LMISSD, SwissLipids and manual
interrogation of on-tissue MALDI MSMS product ion spectra.

CHAPTER 4: DISCUSSION
In this study, we demonstrate for the first time the use of MALDI IMS to identify
lipid abnormalities of MRI-defined pvWMHs within formalin-fixed, human brain tissue. As
previously shown, MALDI of DAN or DHB-coated tissue was effective for the respective
negative or positive ionization of lipids92. MALDI IMS scans conducted in negative mode
m/z 450 – 2000 and positive mode m/z 450-1000 permitted the consistent detection
(>80% of the 21 tissue blocks) of 116 unique ion species across the three scan modes.
Analysis of consistently detected mass peaks elucidated intrasubject differences in lipid
expression between NAWM and pvWMHs for 31 lipid ion species. Lipid profile alterations
were bi-directional, representing increases in 16 mass peaks and decreases in 15 mass
peaks in pvWMHs relative to NAWM. Experimental m/z searches in lipid databases,
LMISSD and SwissLipids, and manual interrogation of MALDI MSMS product ion spectra,
permitted the assignment of lipid ion identities to 27 of the 31 significantly altered mass
peaks. This investigation has exhibited the novel use of MALDI IMS for comparative lipid
profile characterization of healthy and pathological tissue in clinically relevant, formalinfixed, human brain tissue.
The consistent detection of 116 mass peaks amongst all tissue samples
corresponding to positive and negative ions at m/z 450 – 2000 demonstrates the potential
of MALDI IMS for broad, untagged approach to lipid investigations. Although these
consistently detected species do not represent the totality of lipids that are present in
human white matter, as some lipid species may not ionize in the presence of either DAN
or DHB matrix, it does represent a broad profile of the lipid species present in human
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white matter. This application is better suited for a ‘rule-in’ rather than ‘rule-out’ approach
due to the aforementioned poor ionization of certain lipid species, or ion suppression from
readily-ionized molecules such as PC species in positive ion mode 99. This ‘rule-in’
approach is important to consider when assessing lipid abnormalities in formalin-fixed
tissue as formalin is known to degrade the signal of phosphoethanolamines, thus making
phosphoethanolamine abnormalities less apparent100.
Gangliosides are ubiquitously expressed lipids that are highly enriched in neural
tissue101. Gangliosides are an integral membrane component of many cell populations
within the CNS, where they play critical roles in the structure of the plasma membrane,
as well as influencing the localization of proteins within the plasma membrane 102.
Ganglioside abnormalities have previously been associated with neurodegenerative
diseases such as Alzheimer’s disease, stroke, and multiple sclerosis 102,103. Interestingly,
we observed an increase in the intensity of mass peaks associated with negative ions of
GM1 36:1 (18:0) and GM1 38:1 (d20:0) in pvWMHs relative to NAWM. The GM1
ganglioside species have previously been associated with neuroprotective effects 102.
Numerous mechanisms for the neuroprotective effects of GM1 species have been
proposed, including the inhibition nitric oxide synthase activity104, prevention of glutamate
toxicity105, and influencing the activity of protein receptors via membrane microdomain
organization106. Therefore the effects of GM1 species in pvWMHs are likely multimodal,
varying depending on the cell population in-question102. Thus, further work is required to
elucidate what cell population, or populations, are responsible for the observed increase
of GM1 in pvWMHs.
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An interesting observation in the imaging data is that some lipid species elevated
in the pvWMH were also elevated in the adjacent caudate. Our current understanding of
this observation is limited, however, a proposed cause of this may be leakage of biological
macromolecules from vicinal regions into the pvWMH during the development of the
pvWMH. Factors such as localized tissue rarefaction and edema in the pvWMH may play
a role in the leakage of molecules from vicinal regions, and vice-versa13,22. PvWMHs are
known to be progressive, however, molecular mechanisms behind the spreading
pathology of pvWMHs remain somewhat limited107. Whilst speculative, if this leakage
phenomenon were confirmed, this could suggest a potential molecular mechanism for the
propagation of pvWMHs into adjacent regions.
Confident assignment of lipid ion identity is a critical aspect of any investigation of
lipid abnormalities. In the current study, assignment of lipid identity was attempted by
searching experimental m/z values in two independent databases, LipidMAPS and
SwissLipids, and assisted by manual interrogation of product ion spectra generated by
on-tissue MALDI MSMS. A limitation currently facing the use of MALDI IMS for analysis
of formalin-fixed tissue is the difficulty in assigning ion species identities to mass peaks
using MSn. MS1 is unable distinguishing structural isomers, thus demonstrating the need
for MSMS-based identification. Manual interrogation of MSMS spectra for the presence
of characteristic peaks has previously been used to assist lipid identity assignment87.
However, this technique is not feasible for complete structural characterization of all
significantly altered species identified in pvWMHs in the current study. Other publications
in the field of lipid analysis have noted that the popular use of MALDI mass spectrometry
as a tool for protein analysis has contributed to the development of software for the
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identification of proteins, however, software for lipid identification is notably trailing 108,109.
We believe future studies using MALDI IMS for lipid detection would benefit from the
development of species-specific and tissue-specific lipid identification databases.
Conclusions
In conclusion, we have demonstrated the viability of using MALDI IMS for a broad,
untagged approach to lipid detection in archived, formalin-fixed, post-mortem human
brain tissue. This approach permitted the consistent detection of 116 distinct ion species
in 21 tissue blocks from 11 brains. We have shown the application of MALDI IMS for
resolving intrasubject differences in lipid expression by detecting bidirectional differences
in mass peak intensity between pvWMHs and adjacent NAWM. By interrogating two
independent lipid databases, LipidMAPS and SwissLipids, as well as conducting ontissue MALDI MSMS, we assigned tentative lipid ions identities to 27 mass peaks.
Interestingly, two observed differences were increases of the neuroprotective
gangliosides GM1 36:1 (d18:0) and GM1 38:1 (d20:0) in pvWMHs relative to NAWM.
Further investigation is required to identify what cell population is responsible for the
observed elevation in GM1 species and the biological ramifications of elevated GM1 in
WMHs. Assignment of lipid ion identities to the remaining mass peaks represents a
limitation of lipid analysis in formalin-fixed non-embedded post-mortem human tissue,
however, we believe that advancements in lipid-related software will continue to
contribute to high-throughput bioinformatic-scale lipid analysis using MALDI IMS. In
summary, this study demonstrates the potential of MALDI IMS for the purpose of spatialspecific lipid quantification in MRI-defined, formalin-fixed, post-mortem human tissue and
identifies lipid alterations associated with pvWMHs.
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APPENDIX
Supplementary Figures

Neuropathological
Classification
Normal

n

Age ± SD

Male Sex (%)

5

69.4 ± 12.9

2 (40%)

Fixation Length
(months) ± SD
155 ± 3.8

AD

5

75.4 ± 5.5

3 (60%)

136 ± 40.1

CVD

5

72.6 ± 13.2

4 (80%)

134 ± 39.4

AD + CVD

5

82.2 ± 5.8

1 (20%)

160 ± 3.1

Supplementary Table 1: Demographic data from specimen selection including
neuropathological group, age at time of death, sex and fixation lengths (months since
date of autopsy).
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